Sygnature Discovery is a world-leading integrated drug discovery Contract Research Organisation, with over 1000 staff from 53 nationalities, including 900 scientists working on drug discovery programmes. Founded in 2004, we have delivered over 40 pre-clinical compounds, 21 clinical compounds, and our scientists are named on over 170 patent applications. We partner with global pharma, biotech, and NFP organizations, providing integrated drug discovery services from target identification through to candidate nomination. Our co-located teams are experts in protein science, chemistry, computational chemistry, in vitro biology, pharmacology, DMPK, form and formulation services, and project management, with a core therapeutic focus on oncology, inflammation and immunology, as well as neuroscience, metabolic diseases, respiratory, infectious diseases and fibrotic diseases.